Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.
about
Clostridium difficile toxins: mechanism of action and role in disease.Human antibody response to Clostridium difficile toxin A in relation to clinical course of infectionAn update on antibody-based immunotherapies for Clostridium difficile infectionNeutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domainMurine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.Equine hyperimmune serum protects mice against Clostridium difficile spore challengeSerum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycinTheodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies.Clostridium difficile-induced colitis in mice is independent of leukotrienesMechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumabSurvival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamstersSaccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum.Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strainIntravenous immunoglobulin therapy for severe Clostridium difficile colitisTranscutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.Comparison of enterotoxin production, cytotoxin production, serogrouping, and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients.Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin ADevelopment of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease.Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.Clinical update for the diagnosis and treatment of Clostridium difficile infection.Variations in virulence and molecular biology among emerging strains of Clostridium difficile.The enterotoxicity of Clostridium difficile toxins.Immune-based treatment and prevention of Clostridium difficile infection.Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.Neutralization of Clostridium difficile toxin A using antibody combinations.Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutination.Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
P2860
Q24522454-EE7E4FC8-8F3E-4ACF-82E6-4CFD33C62FC3Q24676013-55D35EFB-36D2-4DD8-9436-A0DAD002B56CQ26740788-97E5874F-C7E1-47F1-8D0D-8078DC331C18Q28302768-11FE7787-F5E2-4204-85AB-33F09425C048Q30429490-1D049A00-9602-4F0B-8CB8-7213BE500514Q33865434-DA8C5B1E-FF71-48EA-A598-79E5774EF29FQ34000146-4C0CF541-9A1B-406A-BB56-539F54CC29DDQ34003957-CDA35BB3-4594-4625-B78C-A460E39FEBB7Q34006013-E4505983-3FC4-4779-8A47-D84AF18BF256Q34315661-717A105F-A400-4D72-83A0-0D238D4A2FB1Q34523852-3DF23060-0976-4AFC-BBFC-403125BC86D7Q34644107-52B48FFF-ABEC-44F6-B906-33A72D4A1CC0Q34955629-9B982E5C-F554-4E74-B028-4AA3EB6D2145Q35131944-5343E577-61BD-4171-A7B3-C2451FC6702CQ35155775-904DA8A7-D666-427E-B0F1-B41744A356A7Q35454102-E32FBEAE-B80C-4A53-8E3D-2D842102ACE0Q35532152-CF4ED013-5BDD-4932-BB0F-01FB5882B4AAQ35551627-2A870478-624D-4FDC-BF0D-6334A9338966Q35841034-E9F267C4-B6DC-42DE-9705-88AE7D045878Q35913487-65B08DA2-C27B-43BF-A727-AFB4208C66D7Q36379304-8E0163CB-A9A4-40DD-AFC7-50388934D6FCQ37066853-3499454B-DAD7-464F-A40A-E5E1415A332EQ37067252-812B93F6-68D5-4190-8D61-DDBCB20A8732Q37204536-DB492C6D-B731-43DF-B57D-424C590B09BCQ37246483-425BF028-BAA7-4753-B9EF-375CE795B9B3Q37332203-36E842D6-7A74-4E6F-94AA-A9EA58BFAB28Q37358133-0A82AD5D-340D-479A-8CFC-E095AC85FB39Q37633859-11B00018-1FCD-43F6-89EA-3D8687914C02Q37680481-59B81BAB-F6DF-49DD-B7FB-0DE37D585A19Q37954308-17763C86-9B15-465F-A007-94C9CF604A08Q38350907-5F1CCF83-E904-41F7-BDCB-175A17BEAD47Q39571078-9E2B25AE-8E0C-4103-85E3-356FA791EB76Q39664838-50EC8432-6A23-4EED-B282-E151353EE919Q40012214-5D085D28-55B9-42AD-98AE-611100510FE4Q40233154-370969B1-A5D1-4155-9370-435FC0C82AA0Q41434690-CF1CB8C5-9778-4808-AA11-4A2F1D78D92D
P2860
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Protection against experimenta ...... Clostridium difficile toxin A.
@en
type
label
Protection against experimenta ...... Clostridium difficile toxin A.
@en
prefLabel
Protection against experimenta ...... Clostridium difficile toxin A.
@en
P2093
P2860
P1476
Protection against experimenta ...... Clostridium difficile toxin A.
@en
P2093
P2860
P304
P407
P577
1991-03-01T00:00:00Z